(Q67833723)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

title

"Panic-like" symptomatology in schizophrenic and schizoaffective patients with postpsychotic depression: observations and implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

“Panic-like” symptomatology in schizophrenic and schizoaffective patients with postpsychotic depression: Observations and implications (English)

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

21 November 2022

1 reference

schizophrenic psychology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1778073

21 November 2022

author name string

J. L. Cutler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1778073

21 November 2022

S. G. Siris

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1778073

21 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1778073

21 November 2022

publication date

1 November 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

18 September 2019

https://api.elsevier.com/content/article/PII:0010440X91900258?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

https://api.elsevier.com/content/article/PII:0010440X91900258?httpAccept=text/plain

21 November 2022

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

21 November 2022

published in

Comprehensive Psychiatry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

page(s)

465-473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

Implications of normal brain development for the pathogenesis of schizophrenia

18 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Postpsychotic depression in schizophrenia

21 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

'Revealed' Depression and Drug Treatment for Schizophrenia

21 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Postpsychotic Depressive Symptoms in Hospitalized Schizophrenic Patients

21 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Studies of depressive symptoms in schizophrenia

21 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics

21 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Frequency and differential diagnosis of depressive syndromes in schizophrenia

21 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Depressive symptoms in schizophrenia: comprehensive differential diagnosis

21 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial

21 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

21 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine

21 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Postpsychotic depression and negative symptoms: an investigation of syndromal overlap

21 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications.

21 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder.

21 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Clinical and psychobiological characteristics of simultaneous panic disorder and major depression

21 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Use of mental health services for the treatment of panic disorder.

21 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Major depression in patients with agoraphobia and panic disorder

21 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Panic disorder and major depression. Increased risk of depression, alcoholism, panic, and phobic disorders in families of depressed probands with panic disorder.

21 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Research diagnostic criteria: rationale and reliability

21 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

A rating scale for depression

21 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

A diagnostic interview: the schedule for affective disorders and schizophrenia

21 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Negative v positive schizophrenia. Definition and validation.

21 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia

21 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites

21 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Six-month prevalence of psychiatric disorders in three communities 1980 to 1982.

21 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Cocaine precipitation of panic disorder

21 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

The prevalence of psychiatric disorders in patients with alcohol and other drug problems

21 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Prevalence, onset, and clinical recognition of panic states in hospitalized male alcoholics.

21 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Alcohol use and abuse among diagnosed agoraphobics

21 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Clinical characteristics and response to sodium lactate of patients with infrequent panic attacks.

21 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Social phobia. Review of a neglected anxiety disorder

21 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates

21 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Diazepam in high doses is effective in schizophrenia.

21 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study.

21 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Letter: Are benzodiazepines antipsychotic agents?

21 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

High dose diazepam in schizophrenia.

21 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Relief of chronic intractable hallucinosis in residual schizophrenia with oxazepam

21 November 2022

57

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia

21 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients

21 November 2022

59

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

21 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Acute high-dose parenteral haloperidol treatment of psychosis

21 November 2022

61

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Section B Lorazepam in the treatment of severe anxiety and anxiety associated with psychotic conditions

21 November 2022

64

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Diazepam treatment of early symptoms of schizophrenic relapse.

21 November 2022

65

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia

21 November 2022

66

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

The pharmacologic treatment of schizophrenia: a progress report

21 November 2022

69

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Diazepam in schizophrenia: a preliminary double-blind trial.

21 November 2022

71

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial

21 November 2022

73

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders

21 November 2022

74

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients.

21 November 2022

75

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Itil TM, Keskiner A, Fink M: Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia

21 November 2022

76

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

21 November 2022

77

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Alprazolam intolerance in stable schizophrenic outpatients

21 November 2022

79

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Benzodiazepines in Schizophrenia: A Need for Reassessment

21 November 2022

80

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study

21 November 2022

81

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Drug trials and heterogeneity in schizophrenia: the mean is not the end

21 November 2022

82

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Use of buspirone in the treatment of schizophrenia

21 November 2022

85

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

The treatment of mixed anxiety and depression with loxapine: a controlled comparative study.

21 November 2022

89

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Thiothixene and Thioridazine in Anxiety

21 November 2022

91

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

A double-blind comparison between loxapine and chlordiazepoxide in the treatment of neurotic anxiety

21 November 2022

92

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

The Interaction Between GABA and Dopamine: Implications for Schizophrenia

21 November 2022

99

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Receptors for the Age of Anxiety: Pharmacology of the Benzodiazepines

21 November 2022

100

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia

21 November 2022

102

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Vulnerability--a new view of schizophrenia

21 November 2022

103

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Buspirone: review of its pharmacology and current perspectives on its mechanism of action

21 November 2022

104

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Schizophrenia, panic attacks, and antidepressants.

21 November 2022

105

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Use of Antidepressant Drugs in Schizophrenia

21 November 2022

106

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Antidepressants in panic disorder and agoraphobia

21 November 2022

108

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.

21 November 2022

109

1 reference

https://api.crossref.org/works/10.1016/0010-440X(91)90025-8

21 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1778073%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

1 reference